EATG » GlaxoSmithKline Is Working on a Much Simpler HIV Treatment

GlaxoSmithKline Is Working on a Much Simpler HIV Treatment

While there have been quite a good number of patients on Tivicay® (dolutegravir) already, and some even see it as a revolutionary next step in treatment and the simplification of it, GSK is now reported to work on a fixed-dose combination of dolutegravir and lamivudine (3Tc). Read more in Fortune Magazine.

Source: http://fortune.com/2016/08/29/glaxosmithkline-hiv-treatment/

News categories: HIV treatment, R&D, Pharma industry